Total income from operations grew 12.54 per cent to Rs 319.67 crore from Rs 284.05 crore in the year ago period. Expenditure rose 13.15 per cent to Rs 278.80 crore from Rs 246.39 crore on account of higher manufacturing and employee benefit expenses among others.
Focus on operational efficiency helped improve Ebitda margin by 127 basis points compared with the corresponding quarter in the previous fiscal. Finished dosages continue to be the largest contributor to the business and constituted 42 per cent of stand-alone sales,” it said .
The board today approved fund raising by issue of equity shares to QIB to the extent of Rs 250 crore with applicable greenshoe option through QIP. It also approved split/sub-division of the face value of company’s equity shares from Rs 10 each to Re 1 each, subject to the approval of shareholders.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)